Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genethon

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

17 comunicati stampa

Guarda tutti i comunicati
13/07/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Genethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical Reality
Fonte
Genethon
Emittente
Business Wire
1.00
0
11/03/2026
Eventi
Salute
Scienza
Farmaceutica
Medicina - Varie
Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic Dose in the First Phase of Its Clinical Trial
Fonte
Genethon
Emittente
Business Wire
1.00
0
26/01/2026
Scienza
Infanzia
Biotecnologia
Medicina - Varie
Salute
Vetrine/Shopping
Farmaceutica
Mercato del lavoro
Industria
Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases
Fonte
Genethon
Emittente
Business Wire
1.00
0
14/01/2026
Volontariato/Solidarietà/Non profit
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Genethon Signs Licensing Agreement With AskBio for the Development of an Investigational Gene Therapy for Pompe Disease
Fonte
Genethon
Emittente
Business Wire
1.00
0
06/01/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Genethon Management to Host Partnering Meetings During JP Morgan Healthcare Week, January 12 -16, 2026 in San Francisco, CA
Fonte
Genethon
Emittente
Business Wire
1.00
0
10/10/2025
Multimedialità
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Eventi
Fiere
Industria
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
Fonte
Genethon
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Web e Social Network
Volontariato/Solidarietà/Non profit
Eventi
Industria
Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress
Fonte
Genethon
Emittente
Business Wire
1.00
0
28/07/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster’s First International Summit, Atamyo Therapeutics’ Progress for LGMDs Highlight Genethon’s Most Recent Newsletter
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/05/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
Fonte
Genethon
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0